The FDA has approved Moderna’s mFlusiva, the first mRNA-based seasonal flu vaccine authorized in the United States, for adults 50 and older, according to Spectrum News 1. Moderna expects the vaccine to become available at select retailers in the coming weeks for the 2026-27 respiratory virus season. The FDA granted traditional approval for adults ages 50 to 64 and accelerated approval for those 65 and older while Moderna completes an additional study. A Phase 3 trial involving more than 40,000 adults found mFlusiva was 26.6% more effective than a licensed standard-dose flu vaccine against the study’s flu endpoint, Moderna said. Pharmacies are still awaiting supply and insurance coverage details, while people younger than 50 remain eligible for other FDA-approved flu vaccines.